Document:

Exhibit 10.4

 

 

CDX, INC.

 

INVESTORS’ RIGHTS AGREEMENT

 

March [___], 2014

 

 

 

    	 

    	 

    

 

TABLE OF CONTENTS

 

	 	 	Page
	 	 	 
	Section 1 Definitions	1
	 	 	 
	1.1	Certain Definitions	1
	 	 	 
	Section 2 Registration Rights	3
	 	 	 
	2.1	Requested Registration	3
	2.2	Company Registration	5
	2.3	Registration on Form S-3	6
	2.4	Expenses of Registration	7
	2.5	Registration Procedures	7
	2.6	Indemnification	8
	2.7	Information by Holder	10
	2.8	Restrictions on Transfer	10
	2.9	Rule 144 Reporting	11
	2.10	Market Stand-Off Agreement	12
	2.11	Delay of Registration	12
	2.12	Transfer or Assignment of Registration Rights	12
	2.13	Limitations on Subsequent Registration Rights	13
	2.14	Termination of Registration Rights	13
	 	 	 
	Section 3 Information Covenants	13
	 	 	 
	3.1	Basic Financial Information and Inspection Rights	13
	3.2	Confidentiality	13
	3.3	“Bad Actor” Notice	14
	3.4	Termination of Covenants	14
	 	 	 
	Section 4 Right of First Refusal	14
	 	 	 
	4.1	Right of First Refusal to Significant Holders	14
	 	 	 
	Section 5 Miscellaneous	16
	 	 	 
	5.1	Amendment	16
	5.2	Notices	16
	5.3	Governing Law	17
	5.4	Successors and Assigns	17
	5.5	Entire Agreement	17
	5.6	Delays or Omissions	17
	5.7	Severability	18
	5.8	Titles and Subtitles	18
	5.9	Counterparts	18
	5.10	Telecopy Execution and Delivery	18
	5.11	Jurisdiction; Venue	18
	5.12	Further Assurances	18
	5.13	Termination Upon Change of Control	18
	5.14	Conflict	18

 

    	-i-

    	 

    

 

TABLE OF CONTENTS (continued)

 

	5.15	Attorneys’ Fees	19
	5.16	Aggregation of Stock	19
	5.17	Jury Trial	19

 

    	-ii-

    	 

    

 

CDX, INC.

INVESTORS’ RIGHTS AGREEMENT

 

This Investors’
Rights Agreement (this “Agreement”) is dated as of March [__], 2014, and is between CDx, Inc., a Delaware
corporation (the “Company”), and the persons and entities listed on Exhibit A (each, an “Investor”
and collectively, the “Investors”).

 

Recitals

 

The Investors are parties
to certain Series A Preferred Stock Subscription Agreements, between the Company and each Investor (the “Subscription
Agreements”), and it is a condition to the closing of the sale of the Series A Preferred Stock to the Investors
listed on such Schedule of Investors that the Investors and the Company execute and deliver this Agreement.

 

The parties therefore
agree as follows:

 

Section 1

Definitions

 

1.1          Certain
Definitions. As used in this Agreement, the following terms shall have the meanings set forth below:

 

(a)          “Bad
Actor Disqualification” means any “bad actor” disqualification described in Rule 506(d)(1)(i) through
(viii) under the Securities Act.

 

(b)          “Commission”
shall mean the Securities and Exchange Commission or any other federal agency at the time administering the Securities Act.

 

(c)          “Common
Stock” means the Common Stock of the Company.

 

(d)          “Conversion
Stock” shall mean shares of Common Stock issued upon conversion of the Series A Preferred Stock.

 

(e)          “Exchange
Act” shall mean the Securities Exchange Act of 1934, as amended, or any similar successor federal statute and the
rules and regulations thereunder, all as the same shall be in effect from time to time.

 

(f)          “Holder”
shall mean any Investor who holds Registrable Securities and any holder of Registrable Securities to whom the registration rights
conferred by this Agreement have been duly and validly transferred in accordance with Section 2.12 of this Agreement.

 

(g)          “Indemnified
Party” shall have the meaning set forth in Section 2.6(c).

 

(h)          “Indemnifying
Party” shall have the meaning set forth in Section 2.6(c).

 

(i)          “Initial
Closing” shall mean the date of the initial sale of shares of the Company’s Series A Preferred Stock pursuant
to the Subscription Agreements.

 

    	 

    	 

    

 

(j)          “Initial
Public Offering” shall mean the closing of the Company’s first firm commitment underwritten public offering
of the Company’s Common Stock registered under the Securities Act.

 

(k)          “Initiating
Holders” shall mean any Holder or Holders who in the aggregate hold not less than 50% of the outstanding Registrable
Securities.

 

(l)          “New
Securities” shall have the meaning set forth in Section 4.1(a).

 

(m)          “Other
Selling Stockholders” shall mean persons other than Holders who, by virtue of agreements with the Company,
are entitled to include their Other Shares in certain registrations hereunder.

 

(n)          “Other
Shares” shall mean shares of Common Stock, other than Registrable Securities (as defined below), (including shares
of Common Stock issuable upon conversion of shares of any currently unissued series of Preferred Stock of the Company) with respect
to which registration rights have been granted.

 

(o)          
“Registrable Securities” shall mean (i) shares of Common Stock issued or issuable pursuant to the
conversion of the Shares and (ii) any Common Stock issued as a dividend or other distribution with respect to or in exchange
for or in replacement of the shares referenced in (i) above; provided, however, that Registrable Securities shall
not include any shares of Common Stock described in clause (i) or (ii) above which have previously been registered or which have
been sold to the public either pursuant to a registration statement or Rule 144, or which have been sold in a private transaction
in which the transferor’s rights under this Agreement are not validly assigned in accordance with this Agreement.

 

(p)          The
terms “register,” “registered” and “registration”
shall refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and
applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement.

 

(q)          “Registration
Expenses” shall mean all expenses incurred in effecting any registration pursuant to this Agreement, including, without
limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel
for the Company, blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such
registration, but shall not include Selling Expenses, fees and disbursements of counsel for the Holders and the compensation of
regular employees of the Company, which shall be paid in any event by the Company.

 

(r)          “Restricted
Securities” shall mean any Registrable Securities required to bear the first legend set forth in Section 2.8(b).

 

(s)          “Rule 144”
shall mean Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time,
or any similar successor rule that may be promulgated by the Commission.

 

(t)          “Rule 145”
shall mean Rule 145 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time,
or any similar successor rule that may be promulgated by the Commission

 

    	-2-

    	 

    

 

(u)          “Securities
Act” shall mean the Securities Act of 1933, as amended, or any similar successor federal statute and the rules and
regulations thereunder, all as the same shall be in effect from time to time.

 

(v)         “Selling
Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the sale
of Registrable Securities and fees and disbursements of counsel for any Holder.

 

(w)          “Series A
Preferred Stock” shall mean the shares of Series A Preferred Stock issued pursuant to the Subscription Agreements.

 

(x)          “Shares”
shall mean the Company’s Series A Preferred Stock.

 

(y)          “Significant
Holders” shall have the meaning set forth in Section 4.1.

 

(z)          “Subscription
Agreements” shall have the meaning set forth in the Recitals.

 

(aa)         “Withdrawn
Registration” shall mean a forfeited demand registration under Section 2.1 in accordance with the terms and
conditions of Section 2.4.

 

Section 2

Registration Rights

 

2.1          Requested
Registration. 

 

(a)          Request
for Registration. Subject to the conditions set forth in this Section 2.1, if the Company shall receive from Initiating
Holders a written request signed by such Initiating Holders that the Company effect any registration with respect to all or a part
of the Registrable Securities (such request shall state the number of shares of Registrable Securities to be disposed of by such
Initiating Holders), the Company will:

 

(i)          promptly
give written notice of the proposed registration to all other Holders; and

 

(ii)         as
soon as practicable, file and use its commercially reasonable efforts to effect such registration (including, without limitation,
filing post-effective amendments, appropriate qualifications under applicable blue sky or other state securities laws, and appropriate
compliance with the Securities Act) and to permit or facilitate the sale and distribution of all or such portion of such Registrable
Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders
joining in such request as are specified in a written request received by the Company within 20 days after such written notice
from the Company is mailed or delivered.

 

(b)          Limitations
on Requested Registration. The Company shall not be obligated to effect, or to take any action to effect, any such registration
pursuant to this Section 2.1:

 

(i)          Prior
to the earlier of (A) the five year anniversary of the date of this Agreement or (B) 180 days following the effective
date of the first registration statement filed by the Company covering an underwritten offering of any of its securities to the
general public (or the subsequent date on which all market stand-off agreements applicable to the offering have terminated);

 

    	-3-

    	 

    

 

(ii)         If
the Initiating Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration
statement, propose to sell Registrable Securities and such other securities (if any) the aggregate proceeds of which (after deduction
for underwriter’s discounts and expenses related to the issuance) are less than $30,000,000;

 

(iii)        In
any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting
such registration, qualification, or compliance, unless the Company is already subject to service in such jurisdiction and except
as may be required by the Securities Act;

 

(iv)        After
the Company has initiated two such registrations pursuant to this Section 2.1 (counting for these purposes only (x) registrations
which have been declared or ordered effective and pursuant to which securities have been sold, and (y) Withdrawn Registrations);

 

(v)         During
the period starting with the date 60 days prior to the Company’s good faith estimate of the date of filing of, and ending
on a date 180 days after the effective date of, a Company-initiated registration (or ending on the subsequent date on which all
market stand-off agreements applicable to the offering have terminated); provided that the Company is actively employing
in good faith commercially reasonable efforts to cause such registration statement to become effective;

 

(vi)        If
the Initiating Holders propose to dispose of shares of Registrable Securities that may be registered on Form S-3 pursuant to a
request made under Section 2.3;

 

(vii)       If
the Initiating Holders do not request that such offering be firmly underwritten by underwriters selected by the Initiating Holders
(subject to the consent of the Company); and

 

(viii)      If
the Company and the Initiating Holders are unable to obtain the commitment of the underwriter described in clause (b)(vii) above
to firmly underwrite the offer.

 

(c)          Deferral.
If (i) in the good faith judgment of the board of directors of the Company, the filing of a registration statement covering
the Registrable Securities would be detrimental to the Company and the board of directors of the Company concludes, as a result,
that it is in the best interests of the Company to defer the filing of such registration statement at such time, and (ii) the
Company shall furnish to such Holders a certificate signed by the President of the Company stating that in the good faith judgment
of the board of directors of the Company, it would be detrimental to the Company for such registration statement to be filed in
the near future and that it is, therefore, in the best interests of the Company to defer the filing of such registration statement,
then (in addition to the limitations set forth in Section 2.1(b)(v) above) the Company shall have the right to defer such
filing for a period of not more than 90 days after receipt of the request of the Initiating Holders, and, provided further,
that the Company shall not defer its obligation in this manner more than two times in any twelve-month period.

 

(d)          Other
Shares. The registration statement filed pursuant to the request of the Initiating Holders may, subject to the provisions
of Section 2.1(e), include Other Shares, and may include securities of the Company being sold for the account of the Company.

 

(e)          Underwriting.
The right of any Holder to include all or any portion of its Registrable Securities in a registration pursuant to this Section 2.1
shall be conditioned upon such Holder’s participation in an underwriting and the inclusion of such Holder’s Registrable
Securities to the extent provided herein. If the Company shall request inclusion in any registration pursuant to Section 2.1
of securities being sold for its own account, or if other persons shall request inclusion in any registration pursuant to Section 2.1,
the Initiating Holders shall, on behalf of all Holders, offer to include such securities in the underwriting and such offer shall
be conditioned upon the participation of the Company or such other persons in such underwriting and the inclusion of the Company’s
and such person’s other securities of the Company and their acceptance of the further applicable provisions of this Section 2
(including Section 2.10). The Company shall (together with all Holders and other persons proposing to distribute their securities
through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or
underwriters selected for such underwriting by the Company, which underwriters are reasonably acceptable to a majority-in-interest
of the Initiating Holders.

 

    	-4-

    	 

    

 

Notwithstanding any
other provision of this Section 2.1, if the underwriters advise the Initiating Holders in writing that marketing factors require
a limitation on the number of shares to be underwritten, the number of Registrable Securities and Other Shares that may be so included
shall be allocated as follows: (i) first, among all Holders requesting to include Registrable Securities in such registration
statement based on the pro rata percentage of Registrable Securities held by such Holders, assuming conversion; (ii) second,
to the Other Selling Stockholders (iii) third, to the Company, which the Company may allocate, at its discretion, for its own account,
or for the account of other holders or employees of the Company.

 

If a person who has
requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such person shall
be excluded therefrom by written notice from the Company, the underwriter or the Initiating Holders. The securities so excluded
shall also be withdrawn from registration. Any Registrable Securities or other securities excluded or withdrawn from such underwriting
shall also be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares to
be included in such registration was previously reduced as a result of marketing factors pursuant to this Section 2.1(e),
then the Company shall then offer to all Holders who have retained rights to include securities in the registration the right to
include additional Registrable Securities in the registration in an aggregate amount equal to the number of shares so withdrawn,
with such shares to be allocated among such Holders requesting additional inclusion, as set forth above.

 

2.2          Company
Registration.

 

(a)          Company
Registration. If the Company shall determine to register any of its securities either for its own account or the account
of a security holder or holders, other than a registration pursuant to Section 2.1 or 2.3, a registration relating solely
to employee benefit plans, a registration relating to the offer and sale of debt securities, a registration relating to a corporate
reorganization or other Rule 145 transaction, or a registration on any registration form that does not permit secondary sales,
the Company will:

 

(i)          promptly
give written notice of the proposed registration to all Holders; and

 

(ii)         use
its commercially reasonable efforts to include in such registration (and any related qualification under blue sky laws or other
compliance), except as set forth in Section 2.2(b) below, and in any underwriting involved therein, all of such Registrable
Securities as are specified in a written request or requests made by any Holder or Holders received by the Company within 10 days
after such written notice from the Company is mailed or delivered. Such written request may specify all or a part of a Holder’s
Registrable Securities.

 

(b)          Underwriting.
If the registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company
shall so advise the Holders as a part of the written notice given pursuant to Section 2.2(a)(i). In such event, the right
of any Holder to registration pursuant to this Section 2.2 shall be conditioned upon such Holder’s participation in
such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein.
All Holders proposing to distribute their securities through such underwriting shall (together with the Company, the Other Selling
Stockholders and other holders of securities of the Company with registration rights to participate therein distributing their
securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter
or underwriters selected by the Company.

 

    	-5-

    	 

    

 

Notwithstanding any
other provision of this Section 2.2, if the underwriters advise the Company in writing that marketing factors require a limitation
on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) exclude all Registrable
Securities from, or limit the number of Registrable Securities to be included in, the registration and underwriting. The Company
shall so advise all holders of securities requesting registration, and the number of shares of securities that are entitled to
be included in the registration and underwriting shall be allocated, as follows: (i) first, to the Company for securities
being sold for its own account, and (ii) second, to the Holders requesting to include Registrable Securities in such registration
statement based on the pro rata percentage of Registrable Securities held by such Holders, assuming conversion

 

If a person who has
requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such person shall
also be excluded therefrom by written notice from the Company or the underwriter. The Registrable Securities or other securities
so excluded shall also be withdrawn from such registration. Any Registrable Securities or other securities excluded or withdrawn
from such underwriting shall be withdrawn from such registration.

 

(c)          Right
to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it under
this Section 2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include securities
in such registration.

 

2.3          Registration
on Form S-3. 

 

(a)          Request
for Form S-3 Registration. After its initial public offering, the Company shall use its commercially reasonable efforts
to qualify for registration on Form S-3 or any comparable or successor form or forms. After the Company has qualified for the use
of Form S-3, in addition to the rights contained in the foregoing provisions of this Section 2 and subject to the conditions
set forth in this Section 2.3, if the Company shall receive from a Holder or Holders of Registrable Securities a written request
that the Company effect any registration on Form S-3 or any similar short form registration statement with respect to all or part
of the Registrable Securities (such request shall state the number of shares of Registrable Securities to be disposed of and the
intended methods of disposition of such shares by such Holder or Holders), the Company will take all such action with respect to
such Registrable Securities as required by Section 2.1(a)(i) and (ii).

 

(b)          Limitations
on Form S-3 Registration. The Company shall not be obligated to effect, or take any action to effect, any such registration
pursuant to this Section 2.3:

 

(i)          In
the circumstances described in either Sections 2.1(b)(i), 2.1(b)(iii) or 2.1(b)(v);

 

(ii)         If
the Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration, propose
to sell Registrable Securities and such other securities (if any) on Form S-3 at an aggregate price to the public of less
than $1,000,000; or

 

    	-6-

    	 

    

 

(iii)        If,
in a given twelve-month period, the Company has effected one such registration in such period.

 

(c)          Deferral.
The provisions of Section 2.1(c) shall apply to any registration pursuant to this Section 2.3.

 

(d)          Underwriting.
If the Holders of Registrable Securities requesting registration under this Section 2.3 intend to distribute the Registrable
Securities covered by their request by means of an underwriting, the provisions of Section 2.1(e) shall apply to such registration.
Notwithstanding anything contained herein to the contrary, registrations effected pursuant to this Section 2.3 shall not be
counted as requests for registration or registrations effected pursuant to Section 2.1.

 

2.4          Expenses
of Registration. All Registration Expenses incurred in connection with registrations pursuant to Sections 2.1, 2.2
and 2.3 shall be borne by the Company; provided, however, that the Company shall not be required to pay for any expenses
of any registration proceeding begun pursuant to Sections 2.1 and 2.3 if the registration request is subsequently withdrawn
at the request of the Holders of a majority of the Registrable Securities to be registered or because a sufficient number of Holders
shall have withdrawn so that the minimum offering conditions set forth in Sections 2.1 and 2.3 are no longer satisfied (in
which case all participating Holders shall bear such expenses pro rata among each other based on the number of Registrable
Securities requested to be so registered), unless the Holders of a majority of the Registrable Securities agree to forfeit their
right to a demand registration pursuant to Section 2.1; provided, however, in the event that a withdrawal by
the Holders is based upon material adverse information relating to the Company that is different from the information known or
available (upon request from the Company or otherwise) to the Holders requesting registration at the time of their request for
registration under Section 2.1, such registration shall not be treated as a counted registration for purposes of Section 2.1,
even though the Holders do not bear the Registration Expenses for such registration. All Selling Expenses relating to securities
registered on behalf of the Holders shall be borne by the holders of securities included in such registration pro rata among
each other on the basis of the number of Registrable Securities so registered.

 

2.5          Registration
Procedures. In the case of each registration effected by the Company pursuant to Section 2, the Company will keep
each Holder advised in writing as to the initiation of each registration and as to the completion thereof. At its expense, the
Company will use its commercially reasonable efforts to:

 

(a)          Keep
such registration effective for a period ending on the earlier of the date which is 60 days from the effective date of the registration
statement or such time as the Holder or Holders have completed the distribution described in the registration statement relating
thereto;

 

(b)          Prepare
and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition
of all securities covered by such registration statement for the period set forth in subsection (a) above;

 

(c)          Furnish
such number of prospectuses, including any preliminary prospectuses, and other documents incident thereto, including any amendment
of or supplement to the prospectus, as a Holder from time to time may reasonably request;

 

(d)          Use
its reasonable best efforts to register and qualify the securities covered by such registration statement under such other securities
or Blue Sky laws of such jurisdiction as shall be reasonably requested by the Holders; provided, that the Company shall
not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service
of process in any such states or jurisdictions;

 

    	-7-

    	 

    

 

(e)          Notify
each seller of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in
such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact
required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances
then existing, and following such notification promptly prepare and furnish to such seller a reasonable number of copies of a supplement
to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such
prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing;

 

(f)          Provide
a transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a CUSIP number
for all such Registrable Securities, in each case not later than the effective date of such registration;

 

(g)          Cause
all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar securities
issued by the Company are then listed; and

 

(h)          In
connection with any underwritten offering pursuant to a registration statement filed pursuant to Section 2.1, enter into an
underwriting agreement in form reasonably necessary to effect the offer and sale of Common Stock, provided such underwriting
agreement contains reasonable and customary provisions, and provided further, that each Holder participating in such underwriting
shall also enter into and perform its obligations under such an agreement.

 

2.6          Indemnification. 

 

(a)          To
the extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers, directors and partners,
legal counsel and accountants and each person controlling such Holder within the meaning of Section 15 of the Securities Act,
with respect to which registration, qualification or compliance has been effected pursuant to this Section 2, and each underwriter,
if any, and each person who controls within the meaning of Section 15 of the Securities Act any underwriter, against all expenses,
claims, losses, damages and liabilities (or actions, proceedings or settlements in respect thereof) arising out of or based on:
(i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any prospectus,
offering circular or other document (including any related registration statement, notification or the like) incident to any such
registration, qualification or compliance, (ii) any omission (or alleged omission) to state therein a material fact required
to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation (or alleged violation)
by the Company of the Securities Act, any state securities laws or any rule or regulation thereunder applicable to the Company
and relating to action or inaction required of the Company in connection with any offering covered by such registration, qualification
or compliance, and the Company will reimburse each such Holder, each of its officers, directors, partners, legal counsel and accountants
and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal
and any other expenses reasonably incurred in connection with investigating and defending or settling any such claim, loss, damage,
liability or action; provided that the Company will not be liable in any such case to the extent that any such claim, loss,
damage, liability, or action arises out of or is based on any untrue statement or omission based upon written information furnished
to the Company by such Holder, any of such Holder’s officers, directors, partners, legal counsel or accountants, any person
controlling such Holder, such underwriter or any person who controls any such underwriter, and stated to be specifically for use
therein; and provided, further that, the indemnity agreement contained in this Section 2.6(a) shall not apply
to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent
of the Company (which consent shall not be unreasonably withheld).

 

    	-8-

    	 

    

 

(b)          To
the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as
to which such registration, qualification or compliance is being effected, indemnify and hold harmless the Company, each of its
directors, officers, partners, legal counsel and accountants and each underwriter, if any, of the Company’s securities covered
by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15
of the Securities Act, each other such Holder, and each of their officers, directors and partners, and each person controlling
each other such Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based
on: (i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any
prospectus, offering circular or other document (including any related registration statement, notification, or the like) incident
to any such registration, qualification or compliance, or (ii) any omission (or alleged omission) to state therein a material
fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse the Company and
such Holders, directors, officers, partners, legal counsel and accountants, persons, underwriters, or control persons for any legal
or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss, damage, liability
or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission
(or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon
and in conformity with written information furnished to the Company by such Holder and stated to be specifically for use therein;
provided, however, that the obligations of such Holder hereunder shall not apply to amounts paid in settlement of
any such claims, losses, damages or liabilities (or actions in respect thereof) if such settlement is effected without the consent
of such Holder (which consent shall not be unreasonably withheld); and provided that in no event shall any indemnity under
this Section 2.6 exceed the gross proceeds from the offering received by such Holder, except in the case of fraud or willful
misconduct by such Holder.

 

(c)          Each
party entitled to indemnification under this Section 2.6 (the “Indemnified Party”)
shall give notice to the party required to provide indemnification (the “Indemnifying Party”)
promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the
Indemnifying Party to assume the defense of such claim or any litigation resulting therefrom; provided that counsel for
the Indemnifying Party, who shall conduct the defense of such claim or any litigation resulting therefrom, shall be approved by
the Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense
at such party’s expense; and provided further that the failure of any Indemnified Party to give notice as provided
herein shall not relieve the Indemnifying Party of its obligations under this Section 2.6, to the extent such failure is not
prejudicial. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified
Party, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the
giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation.
Each Indemnified Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably
request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting therefrom.

 

    	-9-

    	 

    

 

(d)          If
the indemnification provided for in this Section 2.6 is held by a court of competent jurisdiction to be unavailable to an
Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to herein, then the Indemnifying Party,
in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party
as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault
of the Indemnifying Party on the one hand and of the Indemnified Party on the other in connection with the statements or omissions
that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative
fault of the Indemnifying Party and of the Indemnified Party shall be determined by reference to, among other things, whether the
untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied
by the Indemnifying Party or by the Indemnified Party and the parties’ relative intent, knowledge, access to information,
and opportunity to correct or prevent such statement or omission. No person or entity will be required under this Section 2.6(d)
to contribute any amount in excess of the gross proceeds from the offering received by such person or entity, except in the case
of fraud or willful misconduct by such person or entity. No person or entity guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person or entity who was not guilty
of such fraudulent misrepresentation.

 

(e)          Notwithstanding
the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting agreement entered
into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.

 

2.7          Information
by Holder. Each Holder of Registrable Securities shall furnish to the Company such information regarding such Holder and
the distribution proposed by such Holder as the Company may reasonably request in writing and as shall be reasonably required in
connection with any registration, qualification, or compliance referred to in this Section 2.

 

2.8          Restrictions
on Transfer.

 

(a)          The
holder of each certificate representing Registrable Securities by acceptance thereof agrees to comply in all respects with the
provisions of this Section 2.8. Each Holder agrees not to make any sale, assignment, transfer, pledge or other disposition
of all or any portion of the Restricted Securities, or any beneficial interest therein, unless and until the transferee thereof
has agreed in writing for the benefit of the Company to take and hold such Restricted Securities subject to, and to be bound by,
the terms and conditions set forth in this Agreement, including, without limitation, this Section 2.8 and Section 2.10,
and:

 

(i)          There
is then in effect a registration statement under the Securities Act covering such proposed disposition and the disposition is made
in accordance with the registration statement; or

 

(ii)         The
Holder shall have given prior written notice to the Company of the Holder’s intention to make such disposition and shall
have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, and the Holder
shall have furnished the Company, at the Holder’s expense, with (i) an opinion of counsel, reasonably satisfactory to
the Company, to the effect that such disposition will not require registration of such Restricted Securities under the Securities
Act or (ii) a “no action” letter from the Commission to the effect that the transfer of such securities without
registration will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, whereupon
the holder of such Restricted Securities shall be entitled to transfer such Restricted Securities in accordance with the terms
of the notice delivered by the Holder to the Company.

 

(b)          Each
certificate representing Registrable Securities shall (unless otherwise permitted by the provisions of this Agreement) be stamped
or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under applicable
state securities laws):

 

    	-10-

    	 

    

 

THE SECURITIES
REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER
THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED
EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO REGISTRATION OR AN EXEMPTION THEREFROM. THE
ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER,
PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS.

 

THE SHARES
REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO (1) RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD
IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN AN INVESTORS’ RIGHTS AGREEMENT, AND (2) VOTING RESTRICTIONS AS SET
FORTH IN A VOTING AGREEMENT AMONG THE COMPANY AND THE ORIGINAL HOLDERS OF THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT THE
PRINCIPAL OFFICE OF THE COMPANY.

 

The Holders consent
to the Company making a notation on its records and giving instructions to any transfer agent of the Restricted Securities in order
to implement the restrictions on transfer established in this Section 2.8.

 

(c)          The
first legend referring to federal and state securities laws identified in Section 2.8(b) stamped on a certificate evidencing
the Restricted Securities and the stock transfer instructions and record notations with respect to the Restricted Securities shall
be removed and the Company shall issue a certificate without such legend to the holder of Restricted Securities if (i) those
securities are registered under the Securities Act, or (ii) the holder provides the Company with an opinion of counsel reasonably
acceptable to the Company to the effect that a sale or transfer of those securities may be made without registration or qualification.

 

(d)          Each
Investor agrees not to make any sale, assignment, transfer, pledge or other disposition of any securities of the Company, or any
beneficial interest therein, to any person other than the Company unless and until the proposed transferee confirms to the reasonable
satisfaction of the Company that neither the proposed transferee nor any of its directors, executive officers, other officers that
may serve as a director or officer of any company in which it invests, general partners or managing members nor any person that
would be deemed a beneficial owner of those securities (in accordance with Rule 506(d) of the Securities Act) is subject to
any Bad Actor Disqualification, except as set forth in Rule 506(d)(2) or (d)(3) under the Securities Act and disclosed, reasonably
in advance of the transfer, in writing in reasonable detail to the Company.

 

2.9          Rule 144
Reporting. With a view to making available the benefits of certain rules and regulations of the Commission that may permit
the sale of the Restricted Securities to the public without registration, the Company agrees to use its commercially reasonable
efforts to:

 

(a)          Make
and keep adequate current public information with respect to the Company available in accordance with Rule 144 under the Securities
Act, at all times from and after ninety (90) days following the effective date of the first registration under the Securities Act
filed by the Company for an offering of its securities to the general public;

 

    	-11-

    	 

    

 

(b)          File
with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act at any time after it has become subject to such reporting requirements; and

 

(c)          So
long as a Holder owns any Restricted Securities, furnish to the Holder forthwith upon written request a written statement by the
Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after 90 days following
the effective date of the first registration statement filed by the Company for an offering of its securities to the general public),
and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy
of the most recent annual or quarterly report of the Company, and such other reports and documents so filed as a Holder may reasonably
request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration.

 

2.10        Market
Stand-Off Agreement. Each Holder shall not sell or otherwise transfer, make any short sale of, grant any option for the
purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, of any Common Stock (or
other securities) of the Company held by such Holder (other than those included in the registration) during the period from the
filing of the registration statement for the Company’s Initial Public Offering filed under the Securities Act that includes
securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities Act through
the end of the 180-day period following the effective date of the registration statement (or such other period as may be requested
by the Company or an underwriter to accommodate regulatory restrictions on (i) the publication or other distribution of research
reports and (ii) analyst recommendations and opinions, including, but not limited to, the restrictions contained in NASD Rule 2711(f)(4)
or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto). The obligations described in this Section 2.10
shall not apply to a registration relating solely to employee benefit plans on Form S-l or Form S-8 or similar forms that may be
promulgated in the future, or a registration relating solely to a transaction on Form S-4 or similar forms that may be promulgated
in the future. The Company may impose stop-transfer instructions and may stamp each such certificate with the second legend set
forth in Section 2.8(b) with respect to the shares of Common Stock (or other securities) subject to the foregoing restriction
until the end of such 180-day (or other) period. Each Holder agrees to execute a market standoff agreement with said underwriters
in customary form consistent with the provisions of this Section 2.10.

 

2.11        Delay
of Registration. No Holder shall have any right to take any action to restrain, enjoin, or otherwise delay any registration
as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2.

 

2.12        Transfer
or Assignment of Registration Rights. The rights to cause the Company to register securities granted to a Holder by the
Company under this Section 2 may be transferred or assigned by a Holder only to a transferee or assignee of not less than
500,000 shares of Registrable Securities (as presently constituted and subject to subsequent adjustments for stock splits, stock
dividends, reverse stock splits, and the like); provided that (i) such transfer or assignment of Registrable Securities
is effected in accordance with the terms of Section 2.8, the Right of First Refusal and Co-Sale Agreement, and applicable
securities laws, (ii) the Company is given written notice prior to said transfer or assignment, stating the name and address
of the transferee or assignee and identifying the securities with respect to which such registration rights are intended to be
transferred or assigned and (iii) the transferee or assignee of such rights assumes in writing the obligations of such Holder
under this Agreement, including without limitation the obligations set forth in Section 2.10.

 

    	-12-

    	 

    

 

2.13        Limitations
on Subsequent Registration Rights. From and after the date of this Agreement, the Company shall not, without the prior
written consent of Holders holding a majority of the Registrable Securities (excluding any of such shares held by any Holders whose
rights to request registration or inclusion in any registration pursuant to this Section 2 have terminated in accordance with
Section 2.14), enter into any agreement with any holder or prospective holder of any securities of the Company giving such
holder or prospective holder any registration rights the terms of which are senior to the registration rights granted to the Holders
hereunder.

 

2.14        Termination
of Registration Rights. The right of any Holder to request registration or inclusion in any registration pursuant to Sections 2.1,
2.2 or 2.3 shall terminate on the earlier of (i) such date, on or after the closing of the Company’s first registered
public offering of Common Stock, on which all shares of Registrable Securities held or entitled to be held upon conversion by such
Holder may immediately be sold under Rule 144 during any 90-day period and (ii) three years after the closing of the
Company’s Initial Public Offering.

 

Section 3

Information Covenants

 

3.1          Basic
Financial Information and Inspection Rights.

 

(a)          Basic
Financial Information. The Company will furnish the following reports to each Holder who owns at least 500,000 Shares and/or
Conversion Stock (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock
splits, and the like):

 

(i)          As
soon as practicable after the end of each fiscal year of the Company, and in any event within 120 days after the end of each fiscal
year of the Company, a consolidated balance sheet of the Company and its subsidiaries, if any, as at the end of such fiscal year,
and consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such year, prepared in accordance
with U.S. generally accepted accounting principles consistently applied, certified by the Chief Financial Officer of the Company;
and

 

(ii)         As
soon as practicable after the end of the first, second and third quarterly accounting periods in each fiscal year of the Company,
and in any event within 45 days after the end of the first, second, and third quarterly accounting periods in each fiscal year
of the Company, an unaudited consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each such
quarterly period, and unaudited consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for
such period, prepared in accordance with U.S. generally accepted accounting principles consistently applied, subject to changes
resulting from normal year-end audit adjustments.

 

3.2          Confidentiality. Anything
in this Agreement to the contrary notwithstanding, no Holder by reason of this Agreement shall have access to any trade secrets
or classified information of the Company. The Company shall not be required to comply with any information rights of Section 3
in respect of any Holder whom the Company reasonably determines to be a competitor or an officer, employee, director or holder
of more than ten percent (10%) of a competitor. Each Holder acknowledges that the information received by them pursuant to this
Agreement may be confidential and for its use only, and it will not use such confidential information in violation of the Exchange
Act or reproduce, disclose or disseminate such information to any other person (other than its employees or agents having a need
to know the contents of such information, and its attorneys), except in connection with the exercise of rights under this Agreement,
unless the Company has made such information available to the public generally.

 

    	-13-

    	 

    

 

3.3          “Bad
Actor” Notice. Each party to this Agreement will promptly notify each other party to this Agreement in writing if
it or, to its knowledge, any person specified in Rule 506(d)(1) under the Securities Act becomes subject to any Bad Actor
Disqualification.

 

3.4          Termination
of Covenants. The covenants set forth in this Section 3 shall terminate and be of no further force and effect after
the closing of the Company’s Initial Public Offering.

 

Section 4

Right of First Refusal

 

4.1          Right
of First Refusal to Significant Holders. The Company hereby grants to each Holder who owns at least 500,000 Shares or
Conversion Stock (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock
splits and the like) (the “Significant Holders”), the right of first refusal to purchase
its pro rata share of New Securities (as defined in this Section 4.1(a)) which the Company may, from time to time,
propose to sell and issue after the date of this Agreement. A Significant Holder’s pro rata share, for purposes of
this right of first refusal, is equal to the ratio of (a) the number of shares of Common Stock owned by such Significant Holder
immediately prior to the issuance of New Securities (assuming full conversion of the Shares and full conversion or exercise of
all outstanding convertible securities, rights, options and warrants held by such Significant Holder) to (b) the total number
of shares of Common Stock outstanding immediately prior to the issuance of New Securities (assuming full conversion of the Shares
and full conversion or exercise of all outstanding convertible securities, rights, options and warrants). Each Significant Holder
shall have a right of over-allotment such that if any Significant Holder fails to exercise its right hereunder to purchase its
pro rata share of New Securities, the other Significant Holders may purchase the non-purchasing Significant Holder’s
portion on a pro rata basis. This right of first refusal shall be subject to the following provisions:

 

(a)          “New
Securities” shall mean any capital stock (including Common Stock and/or Preferred Stock) of the Company whether now
authorized or not, and rights, convertible securities, options or warrants to purchase such capital stock, and securities of any
type whatsoever that are, or may become, exercisable or convertible into capital stock; provided that the term “New
Securities” does not include:

 

(i)          the
Shares and the Conversion Stock;

 

(ii)         securities
issued or issuable to officers, employees, directors, consultants, placement agents, and other service providers of the Company
(or any subsidiary) pursuant to stock grants, option plans, purchase plans, agreements or other employee stock incentive programs
or arrangements approved by the board of directors of the Company;

 

(iii)        securities
issued pursuant to the conversion or exercise of any outstanding convertible or exercisable securities as of this date of this
Agreement;

 

(iv)        securities
issued or issuable as a dividend or distribution on Preferred Stock of the Company or pursuant to any event for which adjustment
is made pursuant to paragraph 4(e), 4(f) or 4(g) of the certificate of incorporation of the Company;

 

(v)         securities
offered pursuant to a bona fide, firmly underwritten public offering pursuant to a registration statement filed under the Securities
Act;

 

    	-14-

    	 

    

 

(vi)        securities
issued or issuable pursuant to the acquisition of another corporation by the Company by merger, purchase of substantially all
of the assets or other reorganization or to a joint venture agreement, provided, that such issuances are approved by the
board of directors of the Company;

 

(vii)       securities
issued or issuable to banks, equipment lessors, real property lessors, financial institutions or other persons engaged in the business
of making loans pursuant to a debt financing, commercial leasing or real property leasing transaction approved by the board of
directors of the Company;

 

(viii)      securities
issued or issuable in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other
similar agreements or strategic partnerships approved by the board of directors of the Company;

 

(ix)         securities
issued to suppliers or third party service providers in connection with the provision of goods or services pursuant to transactions
approved by the board of directors of the Company;

 

(x)          securities
of the Company which are otherwise excluded by the affirmative unanimous vote of the board of directors of the Company; and

 

(xi)         any
right, option or warrant to acquire any security convertible into the securities excluded from the definition of New Securities
pursuant to subsections (i) through (x) above.

 

(b)          In
the event the Company proposes to undertake an issuance of New Securities, it shall give each Significant Holder written notice
of its intention, describing the type of New Securities, and their price and the general terms upon which the Company proposes
to issue the same. Each Significant Holder shall have 10 days after any such notice is mailed or delivered to agree to purchase
such Holder’s pro rata share of such New Securities and to indicate whether such Holder desires to exercise its over-allotment
option for the price and upon the terms specified in the notice by giving written notice to the Company, in substantially the form
attached as Schedule 1, and stating therein the quantity of New Securities to be purchased.

 

(c)          In
the event the Holders fail to exercise fully the right of first refusal and over-allotment rights, if any, within said 10-day period
(the “Election Period”), the Company shall have 90 days thereafter to sell or enter into
an agreement (pursuant to which the sale of New Securities covered thereby shall be closed, if at all, within 90 days from the
date of said agreement) to sell that portion of the New Securities with respect to which the Significant Holders’ right of
first refusal option set forth in this Section 4.1 was not exercised, at a price and upon terms no more favorable to the purchasers
thereof than specified in the Company’s notice to Significant Holders delivered pursuant to Section 4.1(b). In the event
the Company has not sold within such 90-day period following the Election Period, or such 90-day period following the date of said
agreement, the Company shall not thereafter issue or sell any New Securities, without first again offering such securities to the
Significant Holders in the manner provided in this Section 4.1.

 

(d)          The
right of first refusal granted under this Agreement shall expire upon, and shall not be applicable to, the Company’s Initial
Public Offering.

 

(e)          A
Holder will not have a right of first refusal to purchase a pro rata share of New Securities in accordance with this Section 4
and will not be a Significant Holder for purposes of the right of first refusal granted under this Section 4 if, and for so
long as, the Holder, any of its directors, executive officers, other officers that may serve as a director or officer of any company
in which it invests, general partners or managing members or any person that would be deemed a beneficial owner of the securities
of the Company held by the Holder (in accordance with Rule 506(d) of the Securities Act) is subject to any Bad Actor Disqualification,
except as set forth in Rule 506(d)(2) or (d)(3) under the Securities Act.

 

    	-15-

    	 

    

 

Section 5

Miscellaneous

 

5.1          Amendment. Except
as expressly provided herein, neither this Agreement nor any term hereof may be amended, waived, discharged or terminated other
than by a written instrument referencing this Agreement and signed by the Company and the Holders holding a majority of the Registrable
Securities (excluding any of such shares that have been sold to the public or pursuant to Rule 144, and excluding, with respect
to Section 2 (other than Sections 2.8, 2.9 and 2.10), any of such shares held by any Holders whose rights to request
registration or inclusion in any registration pursuant to Section 2 have terminated in accordance with Section 2.14);
provided, however, that Holders purchasing shares of Series A Preferred Stock in a Closing after the date hereof
may become parties to this Agreement, by executing a counterpart of this Agreement without any amendment of this Agreement pursuant
to this paragraph or any consent or approval of any other Holder; and provided, further, that if any amendment, waiver,
discharge or termination operates in a manner that treats any Holder different from other Holders, the consent of such Holder shall
also be required for such amendment, waiver, discharge or termination. Any such amendment, waiver, discharge or termination effected
in accordance with this paragraph shall be binding upon each Holder and each future holder of all such securities of Holder. Each
Holder acknowledges that by the operation of this paragraph, the holders of a majority of the Registrable Securities (excluding
any of such shares that have been sold to the public or pursuant to Rule 144, and excluding, with respect to Section 2
(other than Sections 2.8, 2.9 and 2.10), any of such shares held by any Holders whose rights to request registration or inclusion
in any registration pursuant to Section 2 have terminated in accordance with Section 2.14) will have the right and power
to diminish or eliminate all rights of such Holder under this Agreement.

 

5.2          Notices. All
notices and other communications required or permitted hereunder shall be in writing and shall be mailed by registered or certified
mail, postage prepaid, sent by facsimile or electronic mail (if to an Investor or Holder) or otherwise delivered by hand, messenger
or courier service addressed:

 

(a)          if
to an Investor, to the Investor’s address, facsimile number or electronic mail address as shown in the Company’s records,
as may be updated in accordance with the provisions hereof;

 

(b)          if
to any Holder, to such address, facsimile number or electronic mail address as shown in the Company’s records, or, until
any such Holder so furnishes an address, facsimile number or electronic mail address to the Company, then to the address, facsimile
number or electronic mail address of the last holder of such shares for which the Company has contact information in its records;
or

 

(c)          if
to the Company, to the attention of the Chief Executive Officer or Chief Financial Officer of the Company at 4225 Executive Square
Suite 600, La Jolla, CA 92037, or at such other current address as the Company shall have furnished to the Investors or Holders,
with a copy (which shall not constitute notice) to Elton Satusky, Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road,
Palo Alto, CA 94304.

 

    	-16-

    	 

    

 

Each such notice or
other communication shall for all purposes of this Agreement be treated as effective or having been given (i) if delivered
by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight
prepaid, specifying next-business-day delivery, one business day after deposit with the courier), or (ii) if sent via mail,
at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained receptacle for the deposit
of the United States mail, addressed and mailed as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile
transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the relevant electronic mail address,
if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the
recipient’s next business day. In the event of any conflict between the Company’s books and records and this Agreement
or any notice delivered hereunder, the Company’s books and records will control absent fraud or error.

 

Subject to the limitations
set forth in Delaware General Corporation Law §232(e), each Investor and Holder consents to the delivery of any notice to
stockholders given by the Company under the Delaware General Corporation Law or the Company’s certificate of incorporation
or bylaws by (i) facsimile telecommunication to the facsimile number set forth on Exhibit A (or to any other facsimile
number for the Investor or Holder in the Company’s records), (ii) electronic mail to the electronic mail address set
forth on Exhibit A (or to any other electronic mail address for the Investor or Holder in the Company’s records), (iii) posting
on an electronic network together with separate notice to the Investor or Holder of such specific posting or (iv) any other
form of electronic transmission (as defined in the Delaware General Corporation Law) directed to the Investor or Holder. This consent
may be revoked by an Investor or Holder by written notice to the Company and may be deemed revoked in the circumstances specified
in Delaware General Corporation Law §232.

 

5.3          Governing
Law. This Agreement shall be governed in all respects by the internal laws of the State of California as applied to agreements
entered into among California residents to be performed entirely within California, without regard to principles of conflicts of
law.

 

5.4          Successors
and Assigns. This Agreement, and any and all rights, duties and obligations hereunder, shall not be assigned, transferred,
delegated or sublicensed by any Investor without the prior written consent of the Company. Any attempt by an Investor without such
permission to assign, transfer, delegate or sublicense any rights, duties or obligations that arise under this Agreement shall
be void. Subject to the foregoing and except as otherwise provided herein, the provisions of this Agreement shall inure to the
benefit of, and be binding upon, the successors, assigns, heirs, executors and administrators of the parties hereto.

 

5.5          Entire
Agreement. This Agreement and the exhibits hereto constitute the full and entire understanding and agreement between the
parties with regard to the subjects hereof. No party hereto shall be liable or bound to any other party in any manner with regard
to the subjects hereof or thereof by any warranties, representations or covenants except as specifically set forth herein.

 

5.6          Delays
or Omissions. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing
to any party to this Agreement upon any breach or default of any other party under this Agreement shall impair any such right,
power or remedy of such non-defaulting party, nor shall it be construed to be a waiver of any such breach or default, or an acquiescence
therein, or of or in any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be
deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of
any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any
party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically
set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any party to this Agreement,
shall be cumulative and not alternative.

 

    	-17-

    	 

    

 

5.7           Severability. If
any provision of this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void,
portions of such provision, or such provision in its entirety, to the extent necessary, shall be severed from this Agreement, and
such court will replace such illegal, void or unenforceable provision of this Agreement with a valid and enforceable provision
that will achieve, to the extent possible, the same economic, business and other purposes of the illegal, void or unenforceable
provision. The balance of this Agreement shall be enforceable in accordance with its terms.

 

5.8           Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. All references in this Agreement to sections, paragraphs and exhibits shall, unless
otherwise provided, refer to sections and paragraphs hereof and exhibits attached hereto.

 

5.9           Counterparts. This
Agreement may be executed in any number of counterparts, each of which shall be enforceable against the parties that execute such
counterparts, and all of which together shall constitute one instrument.

 

5.10         Telecopy
Execution and Delivery. A facsimile, telecopy or other reproduction of this Agreement may be executed by one or more parties
hereto and delivered by such party by facsimile or any similar electronic transmission device pursuant to which the signature of
or on behalf of such party can be seen. Such execution and delivery shall be considered valid, binding and effective for all purposes.
At the request of any party hereto, all parties hereto agree to execute and deliver an original of this Agreement as well as any
facsimile, telecopy or other reproduction hereof.

 

5.11         Jurisdiction;
Venue. With
respect to any disputes arising out of or related to this Agreement, the parties consent to the exclusive jurisdiction of, and
venue in, the state courts in Santa Clara County in the State of California (or in the event of exclusive federal jurisdiction,
the courts of the Northern District of California).

 

5.12         Further
Assurances. Each party hereto agrees to execute and deliver, by the proper exercise of its corporate, limited liability
company, partnership or other powers, all such other and additional instruments and documents and do all such other acts and things
as may be necessary to more fully effectuate this Agreement.

 

5.13         Termination
Upon Change of Control. Notwithstanding anything to the contrary herein, this Agreement (excluding any then-existing obligations)
shall terminate upon (a) the acquisition of the Company by another entity by means of any transaction or series of related
transactions to which the Company is party (including, without limitation, any stock acquisition, reorganization, merger or consolidation
but excluding any sale of stock for capital raising purposes) other than a transaction or series of transactions in which the holders
of the voting securities of the Company outstanding immediately prior to such transaction continue to retain (either by such voting
securities remaining outstanding or by such voting securities being converted into voting securities of the surviving entity),
as a result of shares in the Company held by such holders prior to such transaction, at least fifty percent (50%) of the total
voting power represented by the voting securities of the Corporation or such surviving entity outstanding immediately after such
transaction or series of transactions; or (b) a sale, lease or other conveyance of all substantially all of the assets of
the Company.

 

5.14         Conflict. In
the event of any conflict between the terms of this Agreement and the Company’s certificate of incorporation or its bylaws,
the terms of the Company’s certificate of incorporation or its bylaws, as the case may be, will control.

 

    	-18-

    	 

    

 

5.15         Attorneys’
Fees. In the event that any suit or action is instituted to enforce any provision in this Agreement, the prevailing party
in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such
prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses of attorneys
and accountants, which shall include, without limitation, all fees, costs and expenses of appeals.

 

5.16         Aggregation
of Stock. All securities held or acquired by affiliated entities (including affiliated venture capital funds) or persons
shall be aggregated together for purposes of determining the availability of any rights under this Agreement.

 

5.17         Jury
Trial. EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY LAW, ANY AND ALL RIGHT
TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER SOUNDING IN CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS AGREEMENT.
If the waiver of jury trial set forth in this section is not enforceable,
then any claim or cause of action arising out of or relating to this Agreement shall be settled by judicial reference pursuant
to California Code of Civil Procedure Section 638 et seq. before a referee sitting without a jury, such referee to
be mutually acceptable to the parties or, if no agreement is reached, by a referee appointed by the Presiding Judge of the California
Superior Court for Santa Clara County. This paragraph shall not restrict a party from exercising remedies under the Uniform Commercial
Code or from exercising pre-judgment remedies under applicable law.

 

(signature page follows)

 

    	-19-

    	 

    

 

The parties are signing
this Investors’ Rights Agreement as of the date stated in the introductory clause.

 

	 	CDX, INC.
	 	a Delaware corporation
	 	 	 
	 	By:	 

 

	 	Name:	 

 

	 	Title:	 

 

(Signature page to the Investors’
Rights Agreement)

 

    	 

    	 

    

 

The parties are signing
this Investors’ Rights Agreement as of the date stated in the introductory clause.

 

	 	INVESTOR
	 	 
	 	 
	 	(Print investor name)
	 	 
	 	 
	 	(Signature)
	 	 
	 	 
	 	(Print name of signatory, if signing for an entity)
	 	 
	 	 
	 	(Print title of signatory, if signing for an entity)

 

(Signature page to the Investors’
Rights Agreement)

 

    	 

    	 

    

 

EXHIBIT A

 

INVESTORS

 

[Yazbeck Consulting & Investments Group]

[insert address]

[insert fax]

[insert email]

 

    	 

    	 

    

 

SCHEDULE 1

 

NOTICE AND WAIVER/ELECTION OF

RIGHT OF FIRST REFUSAL

 

I do hereby waive
or exercise, as indicated below, my rights of first refusal under the [Amended and Restated] Investors’ Rights
Agreement dated as of [_____________] (the “Agreement”):

 

1.     Waiver
of [10] days’ notice period in which to exercise right of first refusal: (please check only one)

 

		 ̈	WAIVE in full, on behalf of all Holders, the [___]-day notice period provided to exercise
my right of first refusal granted under the Agreement.

 

		 ̈	DO NOT WAIVE the notice period described above.

 

2.     Issuance
and Sale of New Securities: (please check only one)

 

		 ̈	WAIVE in full the right of first refusal granted under the Agreement with respect to the
issuance of the New Securities.

 

		 ̈	ELECT TO PARTICIPATE in $__________ (please provide amount) in New Securities proposed
to be issued by CDx, Inc., a Delaware corporation, representing LESS than my pro rata portion of the aggregate of $[_______]
in New Securities being offered in the financing.

 

		 ̈	ELECT TO PARTICIPATE in $__________ in New Securities proposed to be issued by CDx, Inc.,
a Delaware corporation, representing my FULL pro rata portion of the aggregate of $[_______] in New Securities being offered
in the financing.

 

		 ̈	ELECT TO PARTICIPATE in my full pro rata portion of the aggregate of $[_______] in
New Securities being made available in the financing AND, to the extent available, the greater of (x) an additional $__________
(please provide amount) or (y) my pro rata portion of any remaining investment amount available in the event
other Significant Holders do not exercise their full rights of first refusal with respect to the $[_______] in New Securities being
offered in the financing.

 

Date: ________________

	 	 
	 	(Print investor name)
	 	 
	 	 
	 	(Signature)
	 	 
	 	 
	 	(Print name of signatory, if signing for an entity)
	 	 
	 	 
	 	(Print title of signatory, if signing for an entity)

 

This is neither a commitment to purchase
nor a commitment to issue the New Securities described above. Such issuance can only be made by way of definitive documentation
related to such issuance. CDx, Inc. will supply you with such definitive documentation upon request or if you indicate that you
would like to exercise your first offer rights in whole or in part.Exhibit 10.5

 

SERIES B PREFERRED STOCK AND WARRANT
PURCHASE AGREEMENT

 

THIS SERIES B PREFERRED
STOCK AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is made as of October [___], 2014, by and among
CDx, Inc., a Delaware corporation (the “Company”), and the investors (“Investors”)
listed on Schedule I hereto (the “Schedule of Investors”).

 

1.     Purchase
and Sale of Stock. Subject to the terms and conditions of this Agreement, each Investor agrees, severally and not jointly,
to purchase, and the Company agrees to sell and issue to each Investor, the number of units (each, a “Unit,”
and collectively, the “Units”) set forth in the column designated “Total Number of Units”
opposite such Investor’s name on the Schedule of Investors, at a cash purchase price of $1.10 per Unit (the “Per
Unit Purchase Price,” and the Per Unit Purchase Price multiplied by the aggregate number of Units purchased
by an Investor, the “Purchase Price”). No more than an aggregate of 5,454,545 Units may be issued to
Investors pursuant to this Agreement; provided, however, upon the mutual agreement of the Company and the Placement Agent
(as defined below), an additional 1,818,182 Units may be sold pursuant to this Agreement. Each Unit contains one share (each, a
“Share,” and collectively, the “Shares”) of the Company’s Series B Preferred
Stock, par value $0.001 per share (“Series B Preferred Stock”) and one warrant substantially in the form
of Exhibit A (each, a “Warrant,” and collectively, the “Warrants”),
to purchase Warrant Shares (as defined below) equal to 100% of the Shares purchased by each Investor. The holder of each Warrant
shall be entitled to exercise such Warrant with respect to some or all of the underlying shares of the Company’s Series B
Preferred Stock (the “Warrant Shares”) at a per share exercise price initially equal to $1.10. The Company’s
agreement with each Investor is a separate agreement, and the sale and issuance of the Units to each Investor is a separate sale
and issuance.

 

1.1           Initial
Closing. The purchase, sale and issuance of the Units shall take place at one or more closings (each of which is referred to
in this Agreement as a “Closing”). The initial Closing (the “Initial Closing”)
shall take place at the offices of Wilson Sonsini Goodrich & Rosati, Professional Corporation, 650 Page Mill Road, Palo Alto,
California 94304, at 10:00 a.m. local time on October [___], 2014, or such other date as the Company determines in its sole
discretion. The Initial Closing shall not take place until an aggregate of $499,999.50 in subscriptions for the purchase of at
least 454,545 Units (the “Minimum Offering”) have been accepted by the Company, the funds for the purchase
thereof have been deposited in an escrow account established for such purpose at Signature Bank, and such funds are available for
disbursement. At the Initial Closing, each Investor shall execute and deliver a copy of that certain Registration Rights Agreement,
substantially in the form of Exhibit B (the “Series B Rights Agreement,” and together with this
Agreement, the “Agreements”), by and among the Company and the other parties thereto in respect of the
Series B Preferred Stock held by such investor and the Warrant Shares issuable upon exercise of the Warrant held by such investor.

 

1.2           Subsequent
Closings. If less than all of the Units are sold and issued at the Initial Closing, then, subject to the terms and conditions
of this Agreement, the Company may sell and issue at one or more subsequent closings (each, a “Subsequent Closing”),
on or prior to March 31, 2015 (provided that such period may be extended up to an additional 30 days by mutual agreement of the
Company and the Placement Agent), up to the balance of the unissued Units to such persons or entities as may be approved by the
Company in its sole discretion. Any such sale and issuance in a Subsequent Closing shall be on the same terms and conditions as
those contained herein, and such persons or entities shall, upon execution and delivery of the relevant signature pages, become
parties to, and be bound by, the Agreements, without the need for an amendment to any of the Agreements except to add such person’s
or entity’s name to the appropriate exhibit to such Agreements, and shall have the rights and obligations hereunder and thereunder,
in each case as of the date of the applicable Subsequent Closing. Each Subsequent Closing shall take place at such date, time and
place as shall be approved by the Company in its sole discretion.

 

    	 

    	 

    

 

1.3           Delivery.
At each Closing, the Company will deliver to each Investor in such Closing a certificate registered in such Investor’s name
representing the number of Shares that such Investor is purchasing in such Closing, and an executed Warrant to purchase up to the
number of Warrant Shares equal to 100% of the number of Shares purchased by such Investor in such Closing, against payment of the
purchase price therefor as set forth in the column designated “Total Purchase Price” opposite such Investor’s
name on the Schedule of Investors, by (a) check payable to Signature Bank, as Escrow Agent for CDx, Inc., (b) wire transfer
in accordance with the Company’s instructions, or (c)  any combination of the foregoing.

 

2.     Representations,
Warranties and Covenants of the Company. The Company represents and warrants to each Investor that:

 

2.1           Due
Incorporation, Qualification, etc. The Company (a) is a corporation duly organized, validly existing and in good standing
under the laws of the State of Delaware; (b) has the power and authority to own, lease and operate its properties and carry
on its business as now conducted; and (c) is duly qualified, licensed to do business and in good standing as a foreign corporation
in each jurisdiction where the failure to be so qualified or licensed could reasonably be expected to have a Material Adverse Effect
(as defined below) on the Company. For purposes of this Agreement, “Material Adverse Effect” shall mean
a material adverse effect on (i) the assets, liabilities, results of operations, condition (financial or otherwise), business,
or prospects of the Company taken as a whole; (ii) the transactions contemplated hereby or in any of the Agreements; or (iii) the
ability of the Company to perform its obligations under the Agreements.

 

2.2           Authority.
The execution, delivery and performance by the Company of each Agreement to be executed by the Company and the consummation of
the transactions contemplated thereby (a) are within the power of the Company and (b) have been duly authorized by all
necessary actions on the part of the Company.

 

2.3           Enforceability.
Each Agreement executed, or to be executed, by the Company has been, or will be, duly executed and delivered by the Company and
constitutes, or will constitute, a legal, valid and binding obligation of the Company, enforceable against the Company in accordance
with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement
of creditors’ rights generally and general principles of equity.

 

2.4           Non-Contravention.
The execution and delivery by the Company of each Agreement executed by the Company and the performance and consummation of the
transactions contemplated thereby do not and will not (a) violate the Company’s Certificate of Incorporation or Bylaws
(as amended, the “Charter Documents”) or any material judgment, order, writ, decree, statute, rule or
regulation applicable to the Company; (b) violate any provision of, or result in the breach or the acceleration of, or entitle
any other Person (defined below) to accelerate (whether after the giving of notice or lapse of time or both), any material mortgage,
indenture, agreement, instrument or contract to which the Company is a party or by which it is bound; or (c) result in the
creation or imposition of any Lien (defined below) upon any property, asset or revenue of the Company or the suspension, revocation,
impairment, forfeiture, or nonrenewal of any material permit, license, authorization or approval applicable to the Company, its
business or operations, or any of its assets or properties. For purposes of this Agreement, the following terms shall have the
following meanings: (i) “Person” shall mean an individual, entity, corporation, partnership, association,
limited liability company, limited liability partnership, joint-stock company, trust or unincorporated organization; and (ii) “Lien”
shall mean any mortgage, lien, title claim, assignment, encumbrance, security interest, adverse claim, contract of sale, restriction
on use or transfer or other defect of title of any kind.

 

    	-2-

    	 

    

 

2.5           Capitalization.

 

(a)   Immediately
before the Initial Closing, the Company’s authorized capital stock consists of 37,000,000 shares of Common Stock, par value
$0.005 per share, of which 10,050,000 shares are issued and outstanding; and 22,000,000 shares of Preferred Stock, par value $0.001
per share (the “Preferred Stock”), 3,000,000 shares of which are designated Series A Preferred Stock
(the “Series A Preferred Stock”) and 1,620,000 of which are issued and outstanding, 19,000,000 shares
of which are designated Series B Preferred Stock and none of which are issued or outstanding. The Common Stock, the Series A Preferred
Stock and the Series B Preferred Stock have the rights, preferences, privileges, and restrictions set forth in the Company’s
Amended and Restated Certificate of Incorporation filed on or about the date hereof (the “Restated Certificate”).

 

(b)   The
outstanding shares of Common Stock and Series A Preferred Stock have been duly authorized and validly issued in compliance with
applicable laws, and are fully paid and nonassessable.

 

(c)   The
Company has reserved:

 

(i)          the
Shares for issuance pursuant to this Agreement;

 

(ii)         the
Warrant Shares for issuance upon exercise of the Warrants;

 

(iii)        14,545,454
shares of Common Stock (as may be adjusted in accordance with the provisions of the Restated Certificate) for issuance upon conversion
of the Shares (the “Conversion Shares”), and the Warrant Shares;

 

(iv)        1,818,181
shares of Series B Preferred Stock for issuance upon conversion of outstanding principal amount of convertible promissory notes
and such additional number of shares of Series B Preferred Stock for issuance upon conversion of outstanding accrued interest of
convertible promissory notes; and

 

(v)         454,524
shares of Common Stock for issuance upon exercise of outstanding warrants; and

 

(vi)        5,059,412 shares
of Common Stock authorized for issuance to employees, consultants and directors pursuant to its 2014 Equity Incentive Plan, under
which options to purchase 2,011,562 shares are issued and outstanding as of the date of this Agreement.

 

(d)   All
issued and outstanding shares of the Company’s Common Stock and Preferred Stock (i) have been duly authorized and validly
issued and are fully paid and nonassessable, and (ii) were issued in compliance with all applicable state and federal laws
concerning the issuance of securities.

 

(e)   The
rights, preferences, privileges and restrictions of the Shares are as stated in the Restated Certificate. Each series of Preferred
Stock is convertible into Common Stock on a one-for-one basis as of the date hereof, and the consummation of the transactions contemplated
hereunder will not result in any anti-dilution adjustment or other similar adjustment to the outstanding shares of Preferred Stock.

 

    	-3-

    	 

    

 

(f)   The
Shares, when issued and delivered and paid for in compliance with the provisions of this Agreement, and the Warrant Shares, when
issued and delivered and paid for in compliance with the provisions of this Agreement and the Warrants, will be validly issued,
fully paid and nonassessable. The Conversion Shares have been duly and validly reserved and, when issued in compliance with the
provisions of this Agreement, the Restated Certificate, the Warrants and applicable law, will be validly issued, fully paid and
nonassessable. The Shares, the Warrants, the Warrant Shares and the Conversion Shares will be free of any liens or encumbrances,
other than any liens or encumbrances created by or imposed upon the Investors; provided, however, that the Shares, the Warrants,
the Warrant Shares and the Conversion Shares are subject to restrictions on transfer under U.S. state and/or federal securities
laws and as set forth herein and in the Series B Rights Agreement and the Warrants. Except as set forth in the Series B Rights
Agreement, that certain Investors’ Rights Agreement dated April 3, 2014 between the Company and the investors listed on Exhibit
A thereto (the “Series A Rights Agreement”) and that certain Registration Rights Agreement dated August
14, 2014 between the Company and the investors listed on Schedule I thereto (the “Bridge Rights Agreement,”
and together with the Series A Rights Agreement and the Series B Rights Agreement, the “Rights Agreements”),
the Shares, the Warrants, the Warrant Shares and the Conversion Shares are not subject to any preemptive rights or rights of first
refusal.

 

(g)   Except
for the conversion privileges of the Preferred Stock, the rights provided pursuant to the Rights Agreements and that certain Right
of First Refusal and Co-Sale Agreement dated April 3, 2014, between the Company and the investors listed on Exhibit A thereto,
or as otherwise described in this Agreement, there are no options, warrants or other rights to purchase any of the Company’s
authorized and unissued capital stock.

 

2.6           Securities
Duly Authorized. The Units to be issued to each such Investor, when issued in accordance with the terms of this Agreement,
will be legal, valid and binding obligations of the Company enforceable in accordance with their terms. The shares of Series B
Preferred Stock that are a component of the Units and the shares of Series B Preferred Stock issuable upon exercise of the Warrants,
as well as the Common Stock issuable upon conversion or exercise thereof, when issued in accordance with their terms, will be duly
and validly issued and fully paid and non-assessable. Subject to the accuracy of the representations and warranties of the Investors
set forth in this Agreement, the offer and issuance by the Company of the Units is exempt from registration under the Securities
Act of 1933, as amended (“Securities Act”).

 

2.7           Permits;
Compliance. The Company is in possession of all franchises, grants, authorizations, licenses, permits, easements, variances,
exemptions, consents, certificates, approvals and orders necessary to own, lease and operate its properties and to carry on its
business as it is now being conducted (collectively, the “Company Permits”), and there is no action pending
or, to the Company’s knowledge, threatened regarding suspension or cancellation of any of the Company Permits. The Company
is not in conflict with, or in default or violation of, any of the Company Permits, except for any such conflicts, defaults or
violations which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. Since June
30, 2014, the Company has not received any notification with respect to possible conflicts, defaults or violations of applicable
laws, except for notices relating to possible conflicts, defaults or violations, which conflicts, defaults or violations would
not have a Material Adverse Effect.

 

2.8           Litigation.
There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency,
self-regulatory organization or body pending or, to the Company’s knowledge, threatened against or affecting the Company,
or its business, properties or assets or its officers or directors in their capacity as such, that would have a Material Adverse
Effect. The Company is unaware of any facts or circumstances that might give rise to any of the foregoing. There has not been,
and to the Company’s knowledge, there is not pending or contemplated, any investigation by the Securities and Exchange Commission
involving the Company or any current or former director or executive officer of the Company.

 

    	-4-

    	 

    

 

2.9           Intellectual
Property Rights. To the Company’s knowledge, the Company owns or possesses adequate rights or licenses to use all trademarks,
trade names, service marks, service mark registrations, service names, patents, patent rights, copyrights, original works, inventions,
licenses, approvals, governmental authorizations, trade secrets and other intellectual property rights and all applications and
registrations therefor (“Intellectual Property Rights”) necessary to conduct its business as now conducted
and as presently proposed to be conducted. There is no claim, action or proceeding being made or brought, or to the Company’s
knowledge, being threatened, against the Company regarding its Intellectual Property Rights. The Company has taken reasonable security
measures to protect the secrecy, confidentiality and value of all of its Intellectual Property Rights, except where failure to
take such measures would not, either individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

2.10         Tax
Status. Except for occurrences that would not, either individually or in the aggregate, reasonably be expected to result
in a Material Adverse Effect, the Company (a) has timely made or filed all foreign, federal and state income and all other tax
returns, reports and declarations required by any jurisdiction to which it is subject; (b) has timely paid all taxes and other
governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports and declarations,
except those being contested in good faith; and (c) has set aside on its books provision reasonably adequate for the payment of
all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no unpaid taxes
in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know of no
basis for any such claim.

 

2.11         Subsidiaries.
The Company does not own or control, directly or indirectly, any interest in any corporation, partnership, limited liability company,
association or other business entity.

 

2.12         Approvals.
No consent, approval, order or authorization of, or registration, declaration or filing with, any governmental authority or other
person (including, without limitation, the shareholders of any person) is required in connection with the execution and delivery
of the Agreements executed by the Company and the performance and consummation of the transactions contemplated thereby, other
than such as have been obtained and remain in full force and effect and other than such qualifications or filings under applicable
securities laws as may be required in connection with the transactions contemplated by this Agreement.

 

2.13         No
“Bad Actor” Disqualification. The Company has exercised reasonable care, in accordance with Securities and Exchange
Commission rules and guidance, to determine whether any Covered Person (as defined below) is subject to any of the “bad actor”
disqualifications described in Rule 506(d)(1)(i) through (viii) under the Securities Act (“Disqualification Events”).
To the Company’s knowledge, no Covered Person is subject to a Disqualification Event except for a Disqualification Event
covered by Rule 506(d)(2) or (d)(3) under the Securities Act. The Company has complied, to the extent applicable, with any
disclosure obligations under Rule 506(e) under the Securities Act. “Covered Persons” are those persons
specified in Rule 506(d)(1) under the Securities Act, including the Company; any predecessor or affiliate of the Company;
any director, executive officer, other officer participating in the offering, general partner or managing member of the Company;
any beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting
power; any promoter (as defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time
of the sale of the Units; and any person that has been or will be paid (directly or indirectly) remuneration for solicitation of
purchasers in connection with the sale of the Units (a “Solicitor”), any general partner or managing
member of any Solicitor, and any director, executive officer or other officer participating in the offering of any Solicitor or
general partner or managing member of any Solicitor.

 

    	-5-

    	 

    

 

2.14         No
General Solicitation.  Neither the Company nor any Person participating on the Company’s behalf in the transactions
contemplated hereby has conducted any “general solicitation,” as such term is defined in Regulation D promulgated under
the Securities Act, with respect to the Units being purchased pursuant to this Agreement.

 

2.15         No
Integrated Offering. Neither the Company, nor any of its affiliates, nor any Person acting on its or their behalf, has directly
or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would
require registration under the Securities Act of the issuance of the Units to the Investors. The issuance of the Units to the Investors
will not be integrated with any other issuance of the Company’s securities (past, current or future) for purposes of any
stockholder approval provisions applicable to the Company or its securities.

 

2.16         No
Brokers. Other than the Placement Agent (as defined below), the Company has taken no action that would give rise to any claim
by any Person for brokerage commissions, transaction fees or similar payments relating to this Agreement or the transactions contemplated
hereby.

 

2.17         Form
D; Blue Sky Laws. The Company agrees to file a Form D with respect to the Securities as required under Regulation D within
fifteen business days after the Initial Closing and to provide a copy thereof to the Placement Agent promptly after such filing.
The Placement Agent shall, on or before the Initial Closing, assist the Company in taking such action as the Company shall reasonably
determine is necessary to qualify the Units for sale to the Investors at the applicable Closing pursuant to this Agreement under
applicable securities or “blue sky” laws of the states of the United States (or to obtain an exemption from such qualification),
and the Company shall provide evidence of any such action so taken to the Company on or prior to such Closing.

 

2.18         Disclosure.
The Company understands and confirms that each of the Investors will rely on the foregoing representations in effecting transactions
in the securities of the Company. All disclosure provided to the Investors regarding the Company, its business and the transactions
contemplated hereby, including the schedules to this Agreement, if any, furnished by or on behalf of the Company is true and correct
in all material respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary
in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading.

 

3.     Representations,
Warranties and Covenants of the Investors. Each Investor hereby represents, warrants, and covenants to the Company that:

 

3.1           Authorization.
Such Investor has full power and authority to execute and deliver, and to consummate the transactions contemplated by this Agreement.
All corporate, limited liability company or other similar action on the part of such Investor, its officers, directors, members,
managers and stockholders necessary for (a) the execution and delivery of, and the consummation of the transactions contemplated
by, this Agreement, and (b) as of the Closing, the performance of all obligations of such Investor under this Agreement, has
been taken. This Agreement, upon execution and delivery by such Investor and assuming the due and proper execution and delivery
by the Company, constitutes a legal, valid and binding obligation of such Investor, enforceable in accordance with its terms, except
as may be limited by (y) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to
or affecting the enforcement of creditors’ rights generally, and (z) the effect of rules of law governing the availability
of equitable remedies.

 

    	-6-

    	 

    

 

3.2           Purchase
Entirely for Own Account. Such Investor represents that the Units will be acquired for investment by such Investor for such
Investor’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof,
and that such Investor has no present intention of selling, granting any participation in, or otherwise distributing the same.
By executing this Agreement, such Investor further represents that Investor does not have any contract, undertaking, agreement
or arrangement with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to
any of the Units.

 

3.3           Disclosure
of Information. Such Investor has received all information it considers necessary or appropriate for deciding whether to purchase
the Units. Such Investor further represents that it has had an opportunity to ask questions and receive answers from the Company
regarding the terms and conditions of the offering of the Units and the business, properties, prospects and financial condition
of the Company. Such Investor has received a complete copy of the Company’s Confidential Private Placement Memorandum dated
October 8, 2014, and the Agreements and has reviewed and understands the terms and conditions of such agreements in their entirety.

 

3.4           Investment
Experience. Such Investor is an investor in securities of companies in the development stage and acknowledges that it is able
to appropriately identify the inherent risks associated with, and can bear the economic risk of the total loss of its investment
in the Units, and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits
and risks of the investment in the Units. Such Investor has not been organized for the purpose of acquiring the Units.

 

3.5           Accredited
Investor. Such Investor is an “accredited investor” as defined in Rule 501 of Regulation D promulgated under
the Securities Act.

 

3.6           Restricted
Securities. Such Investor understands that the Units are “restricted securities” as defined in Rule 144 promulgated
under the Securities Act inasmuch as they are being acquired from the Company in a transaction not involving a public offering
and that under such laws and applicable regulations such securities may not be resold without registration under the Securities
Act, except in certain limited circumstances. Such Investor is familiar with Rule 144, as presently in effect, and understands
the resale limitations imposed thereby and by the Securities Act.

 

3.7           Reliance
on Exemptions. Such Investor understands that the Units are being offered and sold in reliance upon specific exemptions from
the registration requirements of the Securities Act and state securities laws and that the Company is relying upon the truth and
accuracy of, and such Investor’s compliance with, the representations, warranties, covenants, agreements, acknowledgments
and understandings of such Investor contained in this Agreement in order to determine the availability of such exemptions and the
eligibility of Investor to acquire the Units.

 

3.8           Further
Limitations on Disposition. Without in any way limiting the representations set forth above, such Investor further agrees not
to make any disposition of all or any portion of the Units unless and until the transferee thereof has agreed in writing for the
benefit of the Company to be bound by this section to the extent this section is applicable, and:

 

(a)   There
is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is
made in accordance with such registration statement; or

 

(b)   Such
Investor shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition
will not require registration of such securities under the Securities Act.

 

    	-7-

    	 

    

 

Each Investor agrees
that it will promptly notify the Company of any material changes in the information set forth in any registration statement regarding
the Investor or its plan of distribution.

 

3.9           Residency.
Such Investor’s principal executive offices, or primary residence, as applicable, are in the jurisdiction set forth under
such Investor’s name on the Schedule of Investors attached hereto.

 

3.10         No
Brokers. Except for Paulson Investment Company, LLC (the “Placement Agent”) or a sub-agent engaged
by the Placement Agent pursuant to that certain Placement Agent Agreement between the Company and the Placement Agent dated September
24, 2014, no broker, investment banker, financial advisor or other individual, corporation, general or limited partnership, limited
liability company, firm, joint venture, association, enterprise, joint securities company, trust, unincorporated organization or
other person or entity is entitled to any broker’s, finder’s, financial advisor’s or other similar fee or commission
in connection with the transactions contemplated by this Agreement based upon arrangements made by or on behalf of such Investor
or of its affiliates.

 

3.11         Additional
Trading Limitations. Such Investor has not directly or indirectly, nor has any Person acting on behalf of or pursuant to any
understanding with such Investor, engaged in any transactions in the securities of the Company (including, without limitations,
any Short Sales involving the Company’s securities) since the earlier to occur of (a) the time that such Investor was first
contacted by the Company or any other Person regarding an investment in the Company and (b) the 20th day prior to the
public announcement of the transactions contemplated by this Agreement. Such Investor covenants that neither it nor any Person
acting on its behalf or pursuant to any understanding with it will engage in any transactions in the securities of the Company
(including Short Sales) prior to the time that the transactions contemplated by this Agreement are publicly disclosed. For purposes
of this section, a “Short Sale” includes, without limitation, all “short sales” as defined in Rule 200
promulgated under Regulation SHO under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, swaps and similar arrangements
(including on a total return basis), and sales and other transactions through non-U.S. broker dealers or foreign regulated brokers.

 

3.12         Legends.
Such Investor agrees that each Share certificate and Warrant certificate, as well as each certificate for Warrant Shares and each
certificate evidencing the shares of Common Stock issuable upon conversion of the Shares shall bear legends in substantially the
following forms:

 

(a)   “THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”) OR ANY STATE SECURITIES LAWS AND ARE “RESTRICTED SECURITIES” AS DEFINED IN RULE 144 PROMULGATED UNDER THE
SECURITIES ACT. THE SECURITIES MAY NOT BE SOLD OR OFFERED FOR SALE OR OTHERWISE DISTRIBUTED EXCEPT (I) IN CONJUNCTION WITH
AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT, (II) IN COMPLIANCE WITH RULE 144, OR (III) PURSUANT
TO AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER OF THESE SECURITIES THAT SUCH REGISTRATION OR COMPLIANCE IS NOT REQUIRED AS
TO SUCH SALE, OFFER OR DISTRIBUTION.”

 

(b)   Any
other legends required by applicable blue sky or state securities laws.

 

The Company need not
register a transfer of any Share or Warrant Share (or components thereof), and may also instruct its transfer agent not to register
a transfer of any Share or Warrant Share (or components thereof), unless the conditions specified in the foregoing legends are
satisfied to the extent applicable.

 

    	-8-

    	 

    

 

4.     Conditions
of Each Investor’s Obligations at the Initial Closing. The obligations of each Investor participating in the Closing
to accept delivery of the Units purchased at the Initial Closing and to pay the Purchase Price therefor are subject to the fulfillment
on or before the Initial Closing of each of the following conditions, any one or more of which may be waived by an Investor with
respect to such Investor’s obligation:

 

4.1           Representations
and Warranties. The representations and warranties contained in Section 2 shall be true in all material respects on and
as of the Initial Closing with the same effect as though such representations and warranties had been made on and as of the date
of the Initial Closing (except to the extent that any such representations and warranties are made as of a specific date, in which
case such representations and warranties shall be true on and as of such date).

 

4.2           Performance.
The Company shall have performed and complied in all material respects with all agreements, obligations and conditions contained
in this Agreement that are required to be performed or complied with by it on or before the Initial Closing, including, but not
limited to, execution and delivery of the Agreements.

 

4.3           Minimum
Offering has been Subscribed for and Accepted. Subscriptions for the Minimum Offering shall have been accepted by the Company,
the funds with respect therefor shall have been deposited into the escrow account established at Signature Bank (or other qualified
financial institution) for such purpose and the escrowed funds are available for disbursement pursuant to written escrow instructions
executed by the Company and the Placement Agent.

 

5.     Conditions
of the Company’s Obligations at the Initial Closing. The obligations of the Company to sell and issue Units to an Investor
participating in the Initial Closing are subject to the fulfillment on or before the Initial Closing of each of the following conditions
by such Investor, any one or more of which may be waived by the Company:

 

5.1           Representations
and Warranties. The representations and warranties of the Investor contained in Section 3 shall be true and correct on
and as of the Initial Closing with the same effect as though such representations and warranties had been made on and as of the
Initial Closing.

 

5.2           Minimum
Offering has been Subscribed for and Accepted. Subscriptions for the Minimum Offering shall have been accepted by the Company,
the funds with respect therefor shall have been deposited into the escrow account established at Signature Bank (or other qualified
financial institution) for such purpose and the escrowed funds are available for disbursement pursuant to written escrow instructions
executed by the Company and the Placement Agent.

 

5.3           Payment
of Purchase Price. The receipt of payment of the full Purchase Price in accordance with Section 1.3.

 

5.4           Performance.
The Investor shall have performed and complied in all material respects with all agreements, obligations and conditions contained
in this Agreement that are required to be performed or complied with by it on or before the Initial Closing, including, but not
limited to, execution and delivery by such Investor of the Series B Rights Agreement.

 

6.     Conditions
of Each Investor’s Obligations at a Subsequent Closing. The obligations of each Investor participating in a Subsequent
Closing to accept delivery of the Units purchased at such Subsequent Closing and to pay the Purchase Price therefor are subject
to the fulfillment on or before such Subsequent Closing of each of the following conditions, any one or more of which may be waived
by an Investor with respect to such Investor’s obligation:

 

    	-9-

    	 

    

 

6.1           Representations
and Warranties. The representations and warranties of the Company contained in Section 2 shall be true and correct on and as
of such Subsequent Closing with the same effect as though such representations and warranties had been made on and as of such Subsequent
Closing (except to the extent that any such representations and warranties are made as of a specific date, in which case such representations
and warranties shall be true on and as of such date).

 

6.2           Performance.
The Company shall have performed and complied in all material respects with all agreements, obligations and conditions contained
in this Agreement that are required to be performed or complied with by it on or before the Subsequent Closing, including, but
not limited to, execution and delivery of the Agreements.

 

7.     Conditions
of the Company’s Obligations at a Subsequent Closing. The obligations of the Company to sell and issue Units to any Investor
participating in a Subsequent Closing are subject to the fulfillment on or before such Subsequent Closing of each of the following
conditions by such Investor, any one or more of which may be waived by the Company:

 

7.1           Representations
and Warranties. The representations and warranties of the Investor contained in Section 3 shall be true and correct on
and as of such Subsequent Closing with the same effect as though such representations and warranties had been made on and as of
such Subsequent Closing.

 

7.2           Payment
of Purchase Price. The receipt of payment of the full Purchase Price in accordance with Section 1.3.

 

7.3           Performance.
The Investor shall have performed and complied in all material respects with all agreements, obligations and conditions contained
in this Agreement that are required to be performed or complied with by it on or before such Subsequent Closing, including, but
not limited to, execution and delivery by such Investor of the Series B Rights Agreement.

 

8.     Miscellaneous.

 

8.1           Survival
of Warranties. The warranties, representations and covenants of the Company and Investors contained in or made pursuant to
this Agreement shall survive for one year after the execution and delivery of this Agreement.

 

8.2           Assignment;
Successors and Assigns. No provision of this Agreement may be assigned by any Investor without the prior written consent of
the Company. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and permitted assigns any rights, remedies, obligations, or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement.

 

8.3           Governing
Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among
California residents entered into and to be performed entirely within California.

 

8.4           Counterparts;
Facsimile Signatures. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Facsimile or other electronically scanned and transmitted
signatures, including by email attachment, shall be deemed originals for all purposes of this Agreement.

 

    	-10-

    	 

    

 

8.5           Titles
and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in
construing or interpreting this Agreement.

 

8.6           Notices,
etc. All notices and other communications required or permitted hereunder shall be in writing and shall be sent by personal
delivery, facsimile, overnight courier or mailed by certified or registered mail, postage prepaid, return receipt requested, to
the facsimile number or address as follows:

 

Company:

 

CDx, Inc.

225 Executive Square,
Suite 600

La Jolla, CA 94037

Attn: Daniel Yazbeck

 

with a copy (which
shall not constitute notice) to:

 

Wilson Sonsini Goodrich
& Rosati, P.C.

650 Page Mill Road

Palo Alto, CA 94304

Facsimile: (650) 493-6811

Attention: Philip H.
Oettinger

 

Investors:

 

To the facsimile
number or address for each respective Investor set forth in the Schedule of Investors.

 

Agent:

 

Paulson Investment
Company, LLC

1331 NW Lovejoy Street, Suite 720

Portland, OR 97209

Facsimile: (503) 248-2391

Attention: Lorraine
Maxfield

 

with a copy (which
shall not constitute notice) to:

 

Murphy & Weiner, P.C.

430 Cambridge Avenue, Suite 100

Palo Alto, CA 94306

Facsimile: (650) 323-1108

Attention: Debra K. Weiner

 

or to such other facsimile
number or address provided to the parties to this Agreement in accordance with this Section 8.6. Such notices or other communications
shall be deemed delivered upon receipt, in the case of overnight delivery, personal delivery or facsimile transmission (as evidenced
by the confirmation thereof), or three days after deposit in the mails (as determined by reference to the postmark).

 

    	-11-

    	 

    

 

8.7           Expenses.
Irrespective of whether any Closing is effected, each party shall pay its own costs and expenses that it incurs with respect to
the negotiation, execution, delivery and performance of this Agreement. If any action at law or in equity is necessary to enforce
or interpret the terms of this Agreement, the prevailing party shall be entitled to attorney’s fees, costs and necessary
disbursements in addition to any other relief to which such party may be entitled.

 

8.8           Amendments
and Waivers. Any term of this Agreement may be amended or modified only in an instrument in writing executed by the Company
and Investors holding a majority of the Units issued and sold as of the time of such amendment or modification. Any amendment effected
in accordance with this paragraph shall be binding upon each holder of any Units purchased under this Agreement at the time outstanding
(including securities into which such securities are convertible), each future holder of all such securities, and the Company.
No waiver of any provision this Agreement shall be binding unless executed in writing by the party to be bound thereby. No waiver
of any provision of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (regardless of whether
similar), nor shall any such waiver constitute a continuing waiver unless otherwise expressly provided.

 

8.9           Independent
Nature of Investors’ Obligations and Rights. The obligations of each Investor under this Agreement are several and not
joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations
of any other Investor under this Agreement. The decision of each Investor to purchase Units pursuant to this Agreement has been
made by such Investor independently of any other Investor. Nothing contained herein, and no action taken by any Investor pursuant
hereto shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity,
or create a presumption that the Investors are in any way acting in concert or a group with respect to such obligations or the
transactions contemplated by this Agreement. Each Investor acknowledges that no other Investor has acted as agent for such Investor
in connection with making its investment hereunder and that no Investor will be acting as agent of such Investor in connection
with monitoring its investment in the Offering Securities or enforcing its rights under this Agreement. Each Investor will be entitled
to independently protect and enforce its rights, including without limitation the rights arising out of this Agreement, and it
shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company
acknowledges that each of the Investors has been provided with the same Agreement for the purpose of closing a transaction with
multiple Investors and not because it was required or requested to do so by any Investor.

 

8.10         Severability.
If one or more provisions of this Agreement are held to be unenforceable under applicable law, such provision shall be excluded
from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable
in accordance with its terms.

 

8.11         Entire
Agreement. This Agreement and the documents referred to herein constitute the entire agreement among the parties and no party
shall be liable or bound to any other party in any manner by any warranties, representations, or covenants except as specifically
set forth herein or therein.

 

(Signature Page Follows)

 

    	-12-

    	 

    

 

IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first above written.

 

	 	COMPANY:
	 	 
	 	CDX, INC.
	 	 	 
	 	By:	 
	 	 	Daniel Yazbeck
	 	 	President and Chief Executive Officer

 

(Signature Page to Series B Preferred
Stock and Warrant Purchase Agreement)

 

    	 

    	 

    

 

IN WITNESS WHEREOF, the parties have executed
this Agreement as of the date first above written.

 

	 	INVESTOR:
	 	 	 
	 	By:	         

 

	 	Name:	      

 

	 	Title:	       

 

(Signature Page to Series B Preferred
Stock and Warrant Purchase Agreement)

 

    	 

    	 

    

 

Schedule I

 

Schedule of Investors

 

	Investors	 	                        	 	
        Purchase Price 

        (New Money)
	 	Total Purchase

Price	 	Total Number of

Units
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

[Add Subsequent Closing(s), as appropriate].

 

    	 

    	 

    

 

Exhibit A

 

Form of Warrant

 

    	 

    	 

    

 

Exhibit B

 

Form of Registration
Rights Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]